PharmaEngine

PharmaEngine Receivables

The Accounts Receivable of PharmaEngine (4162.TWO) as of Nov 18, 2026 is 1.84 B TWD. In the previous year, Accounts Receivable was 174.17 M TWD — a change of 958.87% (higher).

Receivables

1.84 BTWD

YoY

958.87%

Last updated:

Accounts Receivable of PharmaEngine is 2024 1.84 B TWD. Accounts Receivable of PharmaEngine was 2023 174.17 M TWD. It decreases by 958.87% higher compared to the previous year.

The PharmaEngine Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
763.90 M TWD
Jan 1, 2018
31.67 M TWD
Jan 1, 2019
27.70 M TWD
Jan 1, 2020
644.52 M TWD
Jan 1, 2021
160.48 M TWD
Jan 1, 2022
160.34 M TWD
Jan 1, 2023
174.17 M TWD
Jan 1, 2024
1.84 B TWD
The PharmaEngine Receivables history
YEARReceivablesYoY
1.84 BTWD+958.87%
174.17 MTWD+8.63%
160.34 MTWD-0.09%
160.48 MTWD-75.10%
644.52 MTWD+2,226.45%
27.70 MTWD-12.51%
31.67 MTWD-95.85%
763.90 MTWD+17,012.41%
4.46 MTWD+6.77%
4.18 MTWD-25.58%
5.62 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Accounts Receivable of PharmaEngine is 1.84 B TWD in 2024.

Accounts Receivable of PharmaEngine changed from 174.17 M TWD to 1.84 B TWD, representing a 958.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PharmaEngine

All Key Metrics — PharmaEngine